Seeking Alpha
View as an RSS Feed

Spencer Osborne  

View Spencer Osborne's Comments BY TICKER:
Latest  |  Highest rated
  • Orexigen: Contrave Sales On The Cusp Of Anti-Obesity Leadership - Do Not Celebrate Yet [View article]
    Counter...

    Do you have potential to stop stalking and being disingenuous? Your history says no
    May 26, 2015. 11:42 AM | Likes Like |Link to Comment
  • Orexigen: Contrave Sales On The Cusp Of Anti-Obesity Leadership - Do Not Celebrate Yet [View article]
    Counter....

    You are still stalking. You claim to read the things I write, so you either have a very severe reading comprehension issue, or you are being disingenuous. Your comment history demonstrates this.

    I will type this (for about the twentieth time) more slowly so that it can sink in.

    Belviq sales = what a vacuum cleaner does (suck)
    Contrave sales = what a vacuum cleaner does (suck)
    Qsymia sales = what three vacuums do (suck a lot)

    Simple enough for you?
    May 26, 2015. 11:41 AM | Likes Like |Link to Comment
  • Orexigen: Contrave Sales On The Cusp Of Anti-Obesity Leadership - Do Not Celebrate Yet [View article]
    Counter...

    Stop stalking.

    I do not care how many scripts have been written for a particular drug. Further, I do not care which drug works for a person.

    I care about an investment opportunity. In the obesity space, the sKes of all three of these drugs are not where they need to be. The most dismal of the group is Qsymia. The trend lines indicate that the sales gap will widen further.

    I do not care if someone switches from one to the other. You seem incapable of understanding that the things you want to focus on mean jack squat in whether or not these equities will move.
    May 26, 2015. 11:38 AM | Likes Like |Link to Comment
  • Orexigen: Contrave Sales On The Cusp Of Anti-Obesity Leadership - Do Not Celebrate Yet [View article]
    Counter....

    It has nothing to do with corruption. Extra value drug lists are what they are because the pharmacy gets better pricing. Research the issue a bit. You will see how the system works. Cvs and SAMs get better pricing and pass that on to consumers.
    May 26, 2015. 11:34 AM | Likes Like |Link to Comment
  • Orexigen: Contrave Sales On The Cusp Of Anti-Obesity Leadership - Do Not Celebrate Yet [View article]
    Chris....

    Reps are reps.

    The data are the data. The 25% data presented one thing. The 50% data presented a differing thing. The new CVOT, when started, will tell the story
    May 26, 2015. 11:21 AM | Likes Like |Link to Comment
  • Orexigen: Contrave Sales On The Cusp Of Anti-Obesity Leadership - Do Not Celebrate Yet [View article]
    Wm.....

    Safest and most effective are relative terms. Each individual patient will have a unique reaction to a drug.

    If you look ad adverse events, Contrave is in the middle of the pack.
    May 26, 2015. 09:14 AM | Likes Like |Link to Comment
  • Vivus: Qsymia Sales Flatten Again - Third Place Out Of 3 Drugs Nothing To Celebrate [View article]
    D....

    In my opinion Stendra offers a glimmer of light. Q1 sales were not good for Stendra. I did cover the relaunch in a previous article
    May 26, 2015. 07:46 AM | Likes Like |Link to Comment
  • Arena: Belviq Sales Take Big Step Back - Advertising Needed [View article]
    Sedric....

    1. You assume I have no background in accounting. That is a very bad assumption on your part.

    2. You stated I get paid to be here. I do not. I get paid if an article I submit gets published. I do not earn more by simply being here. If you want to cast stones, please try to be more accurate and concise. If you do not understand something, it is usually better to ask a question than to jump to a conclusion.

    3. I did not have one of your posts removed. I did not ask that a post be removed. I do not control what comments get posted, nor do I control which get removed. Yet again, you made another bad assumption that leads you to arriving at yet another bad conclusion.

    Now, you could man up, admit that you made bad assumptions, or you could try to deflect and make up more things.

    Gross revenue on the Vivus proposition is not really the issue. The issue is that the company has tried, and tried, and tried, and tried, and tried, and tried to get a partner and failed in doing so. They want a partner so desperately to help defray the exorbitant costs of trying to launch and market a drug. Some disingenuous Vivus investors, upon realizing that the company us failing, now want to point to the revenue story in a vacuum and spin that into some false reality that somehow Qsymia is a market leader. It us not. It has not been for quite some time. These mental midgets want to convince themselves that somehow their hopes associated with a false reality will somehow have a slight chance of turning things around despite a history of piss poor sales and the ever growing chasm of losses of dollars as well as market share.

    In conclusion.

    1. You are wrong about my understanding of accounting and financials.

    2. You want to tie what is a very, very, very, very, very, very modest income from writing into something that somehow is paramount. It is not. Did I mention that any income is very, very, very, very, very modest. i gave away more to charity THIS EVENING than this article paid. I actually like that my enjoyment in writing allows me to support charities I care about.
    3. You were wrong about me having you comment deleted.
    Are you a big enough person to admit you are jumping to bad conclusions?
    May 26, 2015. 12:35 AM | Likes Like |Link to Comment
  • Arena: Belviq Sales Take Big Step Back - Advertising Needed [View article]
    Sedric.....

    Vivus LOSES money on every script written. End of story
    May 25, 2015. 10:08 PM | Likes Like |Link to Comment
  • Arena: Belviq Sales Take Big Step Back - Advertising Needed [View article]
    Sedric....

    NNope.....I do not get paid to be here.
    May 25, 2015. 10:07 PM | Likes Like |Link to Comment
  • Orexigen: Contrave Sales On The Cusp Of Anti-Obesity Leadership - Do Not Celebrate Yet [View article]
    counter....

    You want to spin.....your stalking agenda has NOTHING to do with keeping readers up to date. Stop stalking. We can all see your nonsense for what it is.
    May 25, 2015. 10:05 PM | 1 Like Like |Link to Comment
  • Orexigen: Contrave Sales On The Cusp Of Anti-Obesity Leadership - Do Not Celebrate Yet [View article]
    counter.....

    Have you read the warnings on your drug of choice?????

    The most unsafe of the three is Qsymia.

    The only one with REMS is Qsymia.

    http://seekingalpha.co...
    May 25, 2015. 10:05 PM | 2 Likes Like |Link to Comment
  • Orexigen: Contrave Sales On The Cusp Of Anti-Obesity Leadership - Do Not Celebrate Yet [View article]
    counter....

    You want people to take Qsymia, which carries with it a REMS program and the longest list of adverse events in the class. The black box warning is essentially meaningless these days.

    Qsymia sales suck. There is no other way to characterize it.

    The sales pace of Qsymia sucks. there is no oyther way to characterize it.

    Vivus was not able to, despite years and years, and years of desparate attempts, find a partner willing to have anything to do with this drug.

    CVS caremark deal.....Sams club deal....These are pay to play deals. Discount the drug enough, and these people will come on board. Why do you think the revenue per bottle is not as good?

    We all get it. You fell in love with the loser of a three horse race and want to find anything that will vindicate your very bad initial assumptions. i feel sorry for people like you, because at this stage you are taking a step beyond simply lying to yourself, and are trying to bring in other sufferers with you.

    Run along stakler.
    May 25, 2015. 10:03 PM | 2 Likes Like |Link to Comment
  • Vivus: Qsymia Sales Win The Week, But Is It Enough? [View article]
    nope...

    they need to get to profits. that is what is critical. After that they do need to show growth.
    May 25, 2015. 12:19 PM | Likes Like |Link to Comment
  • Arena: Belviq Sales Flattening Out - Is It Sector Saturation? [View article]
    counter...

    Could be the imagination of a stalker that lives to stalk me.
    May 25, 2015. 12:18 PM | Likes Like |Link to Comment
COMMENTS STATS
8,603 Comments
7,137 Likes